Use of pharmacokinetic/pharmacodynamic (PKPD) modeling for starting dose selection in first-in-human trials with high-risk monoclonal antibodies.

被引：0
|
作者：
Agoram, B. M. [1 ]
Martin, S. W. [1 ]
Davis, J. [1 ]
机构：
[1] Pfizer Inc, Sandwich, Kent, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 21 条
  • [21] An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
    Stein, Anthony S.
    Bajel, Ashish
    Fleming, Shaun
    Jongen-Lavrencic, Mojca
    Garciaz, Sylvain
    Maiti, Abhishek
    Boissel, Nicolas
    De Botton, Stephane
    Huls, Gerwin A.
    de Leeuw, David C.
    Avigan, David
    Jensen, Kyle
    Demers, Brigitte
    Wagenaar, Timothy
    Mi, Gu
    Ziti-Ljajic, Samira
    Draganov, Dobrin
    Abbadessa, Giovanni
    Wei, Andrew H.
    BLOOD, 2022, 140 : 7476 - 7477
123